(FAGR) Fagron - Ratings and Ratios

Fagron NV (BR:FAGR), a global leader in pharmaceutical compounding, specializes in delivering personalized medical solutions to healthcare providers and patients worldwide. The company operates through three distinct segments: Essentials, Brands, and Compounding Services, each addressing different aspects of pharmaceutical care.

Under the Essentials segment, Fagron offers high-quality raw materials, including APIs and excipients, designed to meet stringent regulatory standards. Their Brands segment features a diverse portfolio of proprietary products, such as DiluCap for customized capsule formulations, Imuno TF Complex for immune system support, and Cleoderm for dermatological treatments. The Compounding Services segment provides tailored solutions, catering to specific patient needs, supported by the Fagron Academy, which offers professional development for healthcare professionals.

The company, rebranded from Arseus NV in 2015, is headquartered in Nazareth, Belgium, and has established a strong presence in over 35 countries. Fagrons commitment to innovation and sustainability is evident in its eco-friendly packaging initiatives and state-of-the-art compounding facilities, ensuring minimal environmental impact while maintaining product quality.

Looking ahead, Fagrons stock is poised for potential growth. The technical data indicates a bullish trend, with the last price exceeding the SMA 20 and SMA 50, suggesting short-term momentum. The low ATR signals manageable volatility, favorable for stable investments. Fundamentally, the high RoE reflects strong profitability, supported by a moderate P/S ratio indicating efficient revenue generation. While the P/E ratio suggests current valuation, the lower forward P/E hints at expected earnings growth, making Fagron an attractive option for investors seeking balanced risk and return.